Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alaunos Therapeutics, Inc. (TCRT) SEC filings page on Stock Titan provides direct access to the companys regulatory disclosures, including current reports, registration statements and financing-related documents. These filings show how Alaunos describes its business as combining T-cell receptor (TCR) cell therapy for solid tumors with a preclinical-stage obesity and metabolic health drug development program centered on a small molecule candidate.
Through its Forms 8-K, Alaunos reports material events such as strategic reprioritization steps, capital raises, changes in executive leadership, governance matters and listing status. Recent 8-Ks detail a registered direct offering of common stock and pre-funded warrants under a shelf registration statement on Form S-3, a private offering of Series A-2 Convertible Preferred Stock with dividend, voting and conversion terms, and a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a research and development agreement. Other 8-Ks describe Nasdaq notices of non-compliance and subsequent confirmation that the company regained compliance, as well as stockholder approvals of amendments to increase authorized common stock and adjust capital structure.
Alaunos Form S-1 registration statement outlines its identity as a preclinical-stage obesity and metabolic health drug development company, while also summarizing its history as a clinical-stage oncology-focused cell therapy company and the August 2023 decision to wind down its TCR-T Library Phase 1/2 trial. The S-1 also explains an equity purchase agreement and related warrant that allow the company, at its discretion, to sell common stock to an institutional investor up to a specified aggregate amount.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as financing structures, conversion prices, dividend rights, share authorization changes and listing compliance updates. Users can quickly scan material agreements, capital markets transactions and corporate actions, and then open the full EDGAR documents for detailed review. This page is a central resource for understanding how Alaunos presents its strategy, risks, and capital structure in official SEC documents.
Alaunos Therapeutics’ shareholders led by Adrian Price filed Amendment No. 4 to their Schedule 13D and proposed a major new financing and governance change. The group reports beneficial ownership of 189,061 shares of common stock, representing 8.6% of the company.
In a letter dated February 24, 2026, Price proposed that HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited invest $7,000,000 in equity or equity-linked securities via a private placement, with pricing to be negotiated and closing after board approval, documentation and any required Nasdaq shareholder approval. The letter says this transaction, if completed, is expected to result in a change of control.
The shareholders asked the board to meet within five business days to negotiate terms, pressed for the appointment of Gerald Bruce as a director, and stated they may buy additional shares, pursue a tender offer or launch an investor relations campaign if the board does not engage. Amendment No. 4 also corrects and updates the list of reporting persons, their addresses and related powers of attorney.
Alaunos Therapeutics reported positive preclinical proof-of-concept data for ALN1003, its lead oral, non-hormonal small-molecule drug candidate for obesity and related metabolic disorders. In two diet-induced obesity mouse studies, ALN1003 produced dose-related body weight loss, favorable body composition changes, and reduced liver weight compared with untreated controls.
ALN1003-treated mice also showed lower liver injury enzymes (ALT, AST, ALP), improved metabolic biomarkers such as glucose and total cholesterol, and macroscopic signs of reduced liver and white fat accumulation. These non-GLP results will guide further preclinical, formulation, manufacturing, and IND-enabling work. Alaunos reported cash and cash equivalents of about $1.9 million as of September 30, 2025, with its cash runway extending into the second quarter of 2026 and plans to seek additional financing.
Alaunos Therapeutics shareholders led by Adrian Price filed an amended Schedule 13D reporting beneficial ownership of 189,061 common shares, or 8.6% of the company. The group sent a letter proposing a $7,000,000 private placement in equity or equity-linked securities by Hexagon ONE Inc, Alimenta Holding Inc and Krakatau Holding Inc, which is anticipated to result in a change of control if completed.
The investors asked the board to negotiate a term sheet within five business days and reiterated their nomination of Gerald Bruce to the board. They indicated they may buy additional shares in the market, launch a tender offer, or run an investor relations campaign if the board does not engage.
Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share. According to the filing, these shares were issued in lieu of cash board fees, meaning the director took stock as compensation for board service. Following this transaction, he beneficially owns 9,589 shares of Alaunos common stock, held directly.
Alaunos Therapeutics director Robert W. Postma received 5,622 shares of common stock on January 12, 2026, as compensation in lieu of board fees at a price of $2.89 per share. Following this grant, he directly holds 43,872 Alaunos shares. He also reports indirect beneficial ownership of 24 shares through his spouse's IRA and 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal.
Alaunos Therapeutics director Jaime Vieser reported receiving additional company stock as compensation. On January 12, 2026, Vieser acquired 5,839 shares of Alaunos Therapeutics common stock at $2.89 per share, described as shares issued in lieu of board fees. After this transaction, Vieser directly holds 32,338 common shares.
Vieser also reports indirect holdings of Alaunos common stock, including 2,100 shares held by the reporter’s children and 13,503 shares held by Brushwood LLC, an entity for which Vieser is the manager. The filing classifies Vieser as a director and indicates the form is filed by one reporting person.
Alaunos Therapeutics, Inc. reported several corporate and R&D updates. The company terminated, effective immediately, its August 14, 2023 engagement letter with Cantor Fitzgerald & Co. as exclusive financial advisor for potential strategic transactions, with no termination fee owed. The board also adopted Amended and Restated Bylaws that add detailed advance notice and disclosure requirements for stockholder director nominations and other business, give the meeting chair authority to rule on compliance, and update various meeting procedures.
The company highlighted that a stockholder group reporting approximately 8.6% ownership has proposed Gerald W. Bruce as a potential director, which the Corporate Governance and Nominating Committee will evaluate. Alaunos provided an update on its preclinical small-molecule obesity program, noting a lead compound and non-GLP mouse data showing statistically significant, dose-related weight loss and improvements in body composition and metabolic parameters. As of September 30, 2025, cash and cash equivalents were about $1.9 million, providing a cash runway into the first quarter of 2026, and the company plans to seek additional financing by the end of that quarter to continue operations and advance the obesity program.
Alaunos Therapeutics, Inc. entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices under a 2019 research and development agreement. The company agreed to pay a total of $285,055 to M.D. Anderson in installments, including $142,528 on or before December 30, 2025, followed by five monthly payments of $28,506 each through May 30, 2026. In return, both parties are providing mutual general releases of claims related to the unpaid invoices, with customary exceptions, including for any breach of the settlement and certain ongoing matters such as Protocol 2006-0676.
Alaunos Therapeutics (TCRT) filed its Q3 2025 10‑Q, highlighting continued cost control alongside funding actions to support its shift to an oral small‑molecule obesity program. The company posted a net loss of $1,159 thousand for the quarter, with operating expenses of $1,187 thousand. Cash and cash equivalents were $1,938 thousand, and stockholders’ equity was $2,803 thousand as of September 30, 2025.
Alaunos raised capital during 2025 via a registered direct offering of common stock and pre‑funded warrants, and private placements of Series A‑1 and Series A‑2 preferred stock. It also entered an equity purchase agreement permitting sales of up to $25.0 million of common stock over 24 months, and issued a five‑year warrant at $4.00 per share in connection with that agreement. The company reports cash runway into the first quarter of 2026 and discloses substantial doubt about its ability to continue as a going concern absent additional financing.
The strategic focus remains on preclinical obesity candidates, with in vitro and in vivo work underway. Alaunos regained compliance with Nasdaq continued listing requirements in August 2025. Common shares outstanding were 2,205,846 as of September 30, 2025.
Alaunos Therapeutics (TCRT) filed a pre‑effective amendment to a mixed shelf registration. The filing registers up to $50,000,000 of primary securities (common stock, preferred stock, debt, and warrants) that may be offered from time to time, and also covers the resale by selling stockholders of up to 217,390 shares issuable upon conversion of Series A‑1 preferred and up to 227,170 shares issuable upon conversion of Series A‑2 preferred.
The company may receive proceeds only from its own future primary offerings; it will not receive proceeds from selling stockholder resales. As context, common shares outstanding were 2,321,829 as of November 3, 2025. The Series A‑1 and Series A‑2 preferred each carry 10% cumulative dividends payable in kind, with initial conversion prices of $2.76 (A‑1) and $4.49 (A‑2). The Series A‑1 includes a beneficial ownership cap of 4.99%, adjustable to 9.99% with notice. TCRT is listed on Nasdaq; the last reported sale price was $2.71 on November 3, 2025.
The company highlights ongoing preclinical work in an oral obesity program and notes prior cost reductions and strategic alternatives under evaluation, alongside risks related to potential dilution and Nasdaq continued listing compliance.